Vertex Pharmaceuticals (VRTX) Expected to Announce Quarterly Earnings on Monday

Key Points

• Vertex will report Q1 2026 results after the market close on Monday, May 4, 2026 at 4:30 PM ET; analysts expect EPS $4.43 and revenue $3.0665 billion.
• In the prior quarter Vertex posted EPS of $5.03 (missed by $0.02) and revenue of $3.19B (+9.5% YoY), and analysts' consensus is a "Moderate Buy" with a $555 price target and FY EPS estimates of $17 (this year) and $19 (next year).
• Insiders sold 80,431 shares worth about $37.9 million over the last quarter (insiders now own 0.20%), while institutional investors hold roughly 90.96% of the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect the company to announce earnings of $4.43 per share and revenue of $3.0665 billion for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.98 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Up 0.0%

Vertex Pharmaceuticals stock opened at $430.42 on Monday. The company has a market capitalization of $109.48 billion, a PE ratio of 28.08, a P/E/G ratio of 1.92 and a beta of 0.36. The firm has a fifty day simple moving average of $457.85 and a two-hundred day simple moving average of $449.02. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $510.77.

Analysts Set New Price Targets

VRTX has been the subject of several recent research reports. Wolfe Research raised shares of Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 price target for the company in a research note on Tuesday, January 6th. Citigroup boosted their price target on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Maxim Group raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and set a $575.00 price target for the company in a research note on Wednesday, March 18th. Evercore boosted their price target on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an "outperform" rating in a research note on Friday, January 23rd. Finally, Canaccord Genuity Group boosted their price target on shares of Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a "hold" rating in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $555.00.

Insider Buying and Selling

In related news, EVP Jonathan Biller sold 1,925 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $886,327.75. Following the completion of the transaction, the executive vice president directly owned 20,819 shares of the company's stock, valued at $9,585,692.17. This represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Amit Sachdev sold 58,613 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president directly owned 58,934 shares of the company's stock, valued at approximately $27,630,027.22. The trade was a 49.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,431 shares of company stock valued at $37,875,167 over the last quarter. 0.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VRTX. Motiv8 Investments LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth about $26,000. Swiss RE Ltd. bought a new position in Vertex Pharmaceuticals in the fourth quarter worth about $28,000. Kelleher Financial Advisors bought a new position in Vertex Pharmaceuticals in the third quarter worth about $39,000. Triumph Capital Management bought a new position in Vertex Pharmaceuticals in the third quarter worth about $43,000. Finally, Sfam LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth about $45,000. 90.96% of the stock is owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.